Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPI-006 + ciforadenant + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Corvus Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CPI-006 + ciforadenant + pembrolizumab is an investigational combination therapy composed of three distinct agents with complementary mechanisms used in oncology clinical trials. CPI-006 is a humanized monoclonal antibody targeting CD73, designed to inhibit adenosine production and thereby modulate the immunosuppressive tumor microenvironment. Ciforadenant is a small molecule antagonist of the adenosine A2A receptor, reducing adenosine-mediated immunosuppression and promoting T cell activity. Pembrolizumab is a humanized monoclonal antibody (IgG4) targeting programmed cell death protein 1 (PD-1) on T cells, blocking the interaction with its ligands PD-L1 and PD-L2 to restore and enhance anti-tumor immune responses[1][2][3][4]. This combination is developed for cancers, particularly in immunotherapy-resistant, high adenosine signature, or checkpoint-inhibitor refractory tumors.
- Other names
- CPI-006 + ciforadenant + pembrolizumab
02
Targets
NT5E (Cluster of Differentiation 73)ADORA2A (Adenosine A₂A Receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CPI-006 + ciforadenant + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPI-006 + ciforadenant + pembrolizumab.